While these two cell lines represent the two most frequent EGFR mutations found in NSCLC, further clinical studies are required to establish the role of dual targeting of PLK1 and EGFR in a clinical setting and in the context of other EGFR mutations. This evidence concerns the gene PLK1 and non-small cell lung carcinoma.